Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 18, 2009 Brian Orelli	Free Drugs! Pfizer's giving over 70 drugs away -- to people who have lost their jobs and health insurance recently and can show financial hardship.
The Motley Fool August 16, 2011 Brian Orelli	Keeping Those Little Blue Pill Sales Up Pfizer wins a patent lawsuit for Viagra.
Chemistry World June 27, 2013 Phillip Broadwith	Ups and downs for erectile dysfunction drugs Spedra (avanafil) aims to compete for a share of the lucrative ED market, trading on the fact that it is much faster-acting than other available drugs.
The Motley Fool May 14, 2008 Brian Lawler	Teaching Old Drugs New Tricks Pfizer's top drugs post mixed results in recent off-label studies.
The Motley Fool November 21, 2008 Brian Orelli	Viagra Stays Behind the Counter All puns about soft sales and wishing something would go up in this market have been removed from this article.
The Motley Fool April 20, 2004 Alyce Lomax	Pfizer's Fight First-quarter earnings give mixed messages on the drug maker's meds.
The Motley Fool September 16, 2008 Brian Lawler	Pfizer Puts Safety First Increased FDA scrutiny may motivate the pharmaceutical's new drug-safety site.
The Motley Fool February 9, 2010 Brian Orelli	Pfizer's Slippery Slope Discount cards for drugs help Pfizer track patients' use.
The Motley Fool October 22, 2007 Brian Orelli	New Warnings Won't Sink ED Drug Sales Shockingly, new safety warnings won't hurt erectile dysfunction drugs. Any investor jumpiness should be looked at as a buying opportunity for smart investors.
Chemistry World February 14, 2007 Victoria Gill	Prescription-free Viagra From today, men in the UK will be able to buy Viagra from their pharmacist without a doctor's prescription. But the trial run of the scheme has fanned the flames of a controversy about how US drug company Pfizer markets the impotence drug.
The Motley Fool May 25, 2011 Brian Orelli	Satisfying Clinical Trial Straightens Up Shares VIVUS' erectile dysfunction drug avanafil works.
Chemistry World December 8, 2015 Jennifer Newton	Pfizer to close Cambridge pain outpost Pfizer plans to shut down its Neusentis site on the outskirts of Cambridge, UK, in a move that will eliminate up to 120 jobs.
BusinessWeek July 8, 2010 Simeon Bennett	Pfizer: Civil Suits for Drug Counterfeiters Pfizer's new tactics against fake drug peddlers have allowed it to recoup more than $5 million. That's still a fraction of its lost sales.
The Motley Fool January 10, 2008 Brian Orelli	Good News for Lucky Men Eli Lilly's erectile dysfunction drug can now be taken daily.
BusinessWeek December 18, 2006 Arlene Weintraub	Pfizer vs. the Counterfeiters Its suit against an Indian man alleging that he sold fake Viagra shows how hard it is to shut down online drug marketers.
InternetNews February 10, 2005 Tim Gray	Microsoft and Pfizer After Viagra Spammers Redmond and the pharmaceutical giant team up to file lawsuits to fight selling and advertising of knock-off drugs.
The Motley Fool May 27, 2005 Nick Baker	Mama Always Said You'd Go Blind Urban legends aside, what do new concerns about Viagra and Cialis mean for investors?
CIO October 28, 2011 Kim S. Nash	Pfizer's Future Depends on IT Transformation With its business model ailing, this pharmaceutical giant tries a new IT formula, including a loyalty discount card, mobile applications aimed at consumers, and a cloud-based tablet CRM system for physicians.
BusinessWeek February 28, 2005 David Kiley	The Little Blue Pill -- And Pals -- Have The Blues Despite gargantuan ad budgets, sales are trailing expectations for all three erectile dysfunction contenders.
The Motley Fool July 13, 2004 Brian Gorman	The "Cialis Promise" Eli Lilly and Icos are offering a free trial of their drug Cialis for men who have never used it before and promise that participants not pleased with the results will receive a voucher for a competing product.
The Motley Fool January 19, 2006 Stephen D. Simpson	Pfizer: Less Bad Is Good Enough Pfizer's quarter wasn't strong, but it was better than expected. The company may not be able to recapture past glories, but the stock is still good idea for long-term.
The Motley Fool November 13, 2009 Brian Orelli	Questioning Pfizer's Integrity Pfizer's epilepsy drug Neurontin has had generic competition for a few years, but it's still plaguing the pharmaceutical giant.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool November 8, 2004 Brian Gorman	Pfizer's Gloom Factor The stock will continue to be depressed, but things will improve if Celebrex's safety is proven.
Managed Care December 2004 John Carroll	Pfizer Touts Medicaid Data In Arguing That DM Works The pharmaceutical giant Pfizer says that its disease management program saved Florida $42 million, but a state watchdog group remains unconvinced.
The Motley Fool February 24, 2011 Brian Orelli	Profit From Personalized Medicine Pfizer's drug works well, but consider these companies instead.
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
The Motley Fool December 21, 2004 Brian Gorman	Pfizer Won't Let Go Pfizer is hoping that Celebrex will survive in some form. But the pharmaceutical giant has also determined that the drug should no longer be advertised to consumers. Its shares were pounded again following its revelation that it would pull such ads.
Chemistry World October 21, 2013 Phillip Broadwith	Counterfeit anxiety pills seized in Switzerland Swiss authorities have intercepted a large shipment of counterfeit tablets in transit between China and Egypt. The four crates contained over a million fake versions of Pfizer's Xanax (alprazolam) pills, which have now been destroyed.
The Motley Fool August 28, 2009 Brian Orelli	Now That's Healthy Innovation UnitedHealth lowers costs through an adherence-incentive program.
The Motley Fool August 3, 2011 Brian Orelli	Ignore Pfizer's Financials for Now It's the pipeline that matters.
The Motley Fool April 19, 2006 Brian Gorman	Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge.
The Motley Fool December 1, 2009 Brian Orelli	Pfizer Takes In an Orphan on the Cheap Steal is a pretty accurate term for the price Pfizer paid for Protalix BioTherapeutics' taliglucerase alfa.
The Motley Fool January 19, 2005 Stephen D. Simpson	Pfizer Doesn't Give Much Fizz The company reports mediocre earnings as investors remain nervous about the drug sector.
BusinessWeek May 20, 2009 Maria Bartiromo	Pfizer's Kindler on Health-Care Reform and the Wyeth Deal Pfizer's CEO discusses its acquisition of Wyeth and its plan to provide some drugs for free to those without jobs and insurance.
Chemistry World June 24, 2011 Andrew Turley	Pfizer to Keep 350 Jobs at Sandwich US drug giant Pfizer has said that it will keep 350 jobs at its site in Sandwich, UK.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008.
The Motley Fool August 29, 2011 Brian Orelli	Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive.
The Motley Fool December 10, 2010 Brian Orelli	Was This Drug Destined for Failure? Pfizer announces that it's pulling Thelin off the market, and withdrawing the marketing application with the Food and Drug Administration, because a new side effect was discovered.
The Motley Fool December 1, 2011 John Grgurich	Pfizer Losing Lipitor Patent: What Investors Need to Know The patent ends today.
The Motley Fool October 20, 2005 Stephen D. Simpson	Pfizer Fizzles Disappointing guidance could have this giant pharmaceutical company retesting its lows. This is likely a good time for long-termers to do their due diligence, since they'll probably have some time to get into the stock.
The Motley Fool May 17, 2004 Roger Nusbaum	Diagnosing Pfizer Can Pfizer, the pharmaceutical company, outperform the market?
The Motley Fool September 30, 2011 Brian Orelli	Pfizer's Fungus Failure A combination treatment doesn't work.
BusinessWeek July 2, 2007 Arlene Weintraub	Lifestyle Drug Binge The huge profits in weight-loss and other treatments makes them hard for drugmakers to resist. But safety risks abound.
The Motley Fool August 18, 2010 Brian Orelli	No Pain Here as Jazz Shares Rocket Investors are all jazzed up about Jazz Pharmaceuticals
Pharmaceutical Executive November 1, 2006 Sarah Houlton	Global Report: 'Bout Time The European Union has been late to enter the fight against counterfeiting. Fed up, Parliament has passed a proposal designed to give its countries the nudge they need.
Managed Care December 2000	How To Save Money on Prescriptions There are ways for low-income groups to avoid paying top dollar for prescriptions. Here's one way physicians can educate consumers...
The Motley Fool July 20, 2005 Stephen D. Simpson	Pfizer's Long Road Back It took time for Pfizer to reach a trough and it will take time to climb out. But over the long haul this could prove to be a solid pick.
CIO October 28, 2011 Kim S. Nash	Challenging Times for Pfizer As drug patents expire, the pharmaceutical giant is investing in technology and emerging markets while cutting back on R&D and labor.